tiprankstipranks
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
US Market
Holding CTNM?
Track your performance easily

Contineum Therapeutics, Inc. Class A (CTNM) Ownership - Who Owns Contineum Therapeutics, Inc. Class A?

168 Followers

Contineum Therapeutics, Inc. Class A (CTNM) Ownership Overview

3.73%8.01%51.40%3.78%33.08%
51.40% Other Institutional Investors
3.78% ETFs
33.08% Public Companies and
Individual Investors
The ownership structure of Contineum Therapeutics, Inc. Class A (CTNM) stock is a mix of institutional, retail, and individual investors. Approximately 63.19% of the company’s stock is owned by Institutional Investors, 3.73% is owned by Insiders, and 33.08% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$29029025

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
1,516,668Institution7.96%23,296,020
918,163Institution4.82%14,102,984
523,847Insider2.75%8,046,290
445,801Institution2.34%6,847,503
425,006Institution2.23%6,528,092
392,800Institution2.06%6,033,408
312,500Institution1.64%4,800,000
258,800Institution1.36%3,975,168
218,440Institution1.15%3,355,238
216,967Institution1.14%3,332,613

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
425,006Institution2.23%6,528,092
392,800Institution2.06%6,033,408
258,800Institution1.36%3,975,168
216,967Institution1.14%3,332,613
78,049Institution0.41%1,198,833
70,557Institution0.37%1,083,756
34,407Institution0.18%528,492
19,870Institution0.10%305,203
9,388Institution0.05%144,200
6,016Institution0.03%92,406

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
299,583Institution1.57%5,021,011
152,324Institution0.80%2,339,697
115,078Institution0.60%1,928,707
26,030Institution0.14%436,263
27,980Institution0.15%429,773
24,753Institution0.13%380,206
26,457Institution0.14%372,779
12,976Institution0.07%199,311
4,825Institution0.03%74,112
3,184Institution0.02%53,364

FAQ

Who Owns Contineum Therapeutics, Inc. Class A (CTNM)?
According to the latest TipRanks data, approximately 51.40% of the company's stock is held by institutional investors, 3.73% is held by insiders, and 33.08% is held by retail investors.
    What percentage of Contineum Therapeutics, Inc. Class A (CTNM) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 51.40% of Contineum Therapeutics, Inc. Class A (CTNM) stock is held by institutional investors.
      What percentage of Contineum Therapeutics, Inc. Class A (CTNM) stock is held by retail investors?
      According to the latest TipRanks data, approximately 33.08% of Contineum Therapeutics, Inc. Class A (CTNM) stock is held by retail investors.
        Who owns the most shares of Contineum Therapeutics, Inc. Class A (CTNM)?
        Joseph Edelman owns the most shares of Contineum Therapeutics, Inc. Class A (CTNM).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis